Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →Dabur's Q2 FY26 consolidated revenue grew 5.4% YoY, with India FMCG up 5.7% and international business up 7.7% in INR terms.
✓ Verified against BSE filing
Dabur's Q2 FY26 consolidated revenue grew 5.4% YoY, with India FMCG up 5.7% and international business up 7.7% in INR terms. Operating profit and PAT grew ahead of revenue at 6.4% and 6.5% respectively, supported by price increases and cost savings. The quarter was disrupted by the GST rate cut announcement, which caused a temporary trade destocking impact of ~INR 100 crore (3-4% of sales). HVC portfolio grew 8.9%, Fitkari portfolio 14%, and Honey 28%, while beverages remained flat due to weather. Management guided for mid-to-high single-digit revenue growth in H2, backed by winter season tailwinds, GST benefits, and rural recovery. Key risks include lingering GST transition effects in October, potential US tariffs, and geopolitical issues in Nepal.
दबूर की दूसरी तिमाही (Q2 FY26) में कुल कमाई पिछले साल से 5.4% बढ़ी। भारत में एफएमसीजी कारोबार 5.7% और अंतरराष्ट्रीय कारोबार 7.7% बढ़ा। कंपनी का मुनाफा कमाई से ज्यादा बढ़ा - ऑपरेटिंग मुनाफा 6.4% और कुल मुनाफा 6.5% बढ़ा, क्योंकि कीमतें बढ़ाई गईं और लागत बचाई गई। जीएसटी दर कटौती की घोषणा से तिमाही में अस्थायी रूप से करीब 100 करोड़ रुपये का स्टॉक घटा (बिक्री का 3-4%)। हर्बल उत्पादों की बिक्री 8.9%, फिटकरी 14% और शहद 28% बढ़ी, जबकि पेय पदार्थ मौसम के कारण स्थिर रहे। कंपनी को सर्दी, जीएसटी लाभ और गांवों में सुधार से दूसरी छमाही में 5-9% कमाई बढ़ने की उम्मीद है। जोखिमों में अक्टूबर में जीएसटी का बचा असर, अमेरिकी टैरिफ और नेपाल में राजनीतिक मुद्दे शामिल हैं।
0 delivered, 0 close, 2 missed.
View Promises →GST transition disruption may extend into October
View Risks →Full transcript text is available on this route.
Read Transcript →Temporary disruption due to trade destocking after GST rate cut announcement.
Health, wellness, and personal care portfolio outperformed overall India FMCG.
Premium variants like Sundarbans and Organic Honey drove strong performance.
Management maintained hygiene by not increasing pipeline despite GST disruption.
Management expects second-half revenue growth in mid-to-high single digits, backed by low-to-mid single-digit volume growth.
Management indicated margins will be better than top line, supported by cost savings of ~INR 60 crore in H1 and continued initiatives.
Capital allocation of INR 500 crore for minority/majority stakes in digital-first brands within existing categories (HPC, healthcare, foods).
Management expects high single-digit consolidated revenue growth for FY26, with Q2 likely double-digit due to a low base.
Due to a favorable base (5.5% decline last year), Q2 is expected to deliver double-digit growth, though beverages may be low single-digit.
Management targets a significant improvement in operating margin for the full year, supported by premiumization and cost initiatives.
Company is scouting for M&A targets in wellness foods and health, with a path to profitability equitative to base margins.
Management noted that old-price inventory is still being flushed out, impacting October sales for the first 15-16 days.
CFO highlighted a 1.25-1.5% gap between output and input GST rates, which could require price increases or cost renegotiations.
Nepal business declined 15% due to political disturbance; US tariffs impacted Badshah exports. Management noted these as unforeseen headwinds.
Management flagged ~8% inflation in edible oils, which could pressure gross margins if not fully mitigated by price hikes and savings.
Increased competition from Colgate and in hair oils has led to higher BTL spending, netting off from top line and pressuring gross margins.
Unseasonal rains and a short summer severely impacted beverages and glucose, leading to a ~30% decline in glucose and low single-digit beverage growth.
Analysts raised concerns about reduced disclosures in the investor presentation, which may hinder detailed performance tracking.
Mentioned in Q2 FY25, Q4 FY25
Beverage segment faces heightened competition from Campa Cola and others, with management expecting only low to mid-single-digit growth in FY26.
Mentioned in Q1 FY25, Q2 FY25
Currency depreciation in Egypt and Turkey caused a translation loss of INR 181 crore in H1, impacting reported international profitability.
Mentioned in Q1 FY25, Q2 FY25
Management expects the home care portfolio to grow from INR 700 crore to INR 1,000 crore in a two- to three-year time frame.
Mentioned in Q2 FY25, Q3 FY25
Urban consumption growth has moderated to ~5%, impacting categories like juices and healthcare supplements.
Management expects second-half revenue growth in mid-to-high single digits, backed by low-to-mid single-digit volume growth.
Management noted that old-price inventory is still being flushed out, impacting October sales for the first 15-16 days.
View Risks →